Department of Emergency and Organ Transplantation - Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, and.
Department of Basic Medical Sciences, Neurosciences and Sense Organs - Section of Respiratory Disease, University of Bari Aldo Moro, Bari, Italy.
JCI Insight. 2017 Sep 7;2(17). doi: 10.1172/jci.insight.94379.
In obese subjects with obstructive sleep apnea (OSA), chronic intermittent hypoxia (CIH) may be linked to systemic and adipose tissue inflammation.
We obtained abdominal subcutaneous adipose tissue biopsies from OSA and non-OSA obese (BMI > 35) subjects at baseline and after 24 weeks (T1) of weight-loss intervention plus continuous positive airway pressure (c-PAP) or weight-loss intervention alone, respectively. OSA subjects were grouped according to good (therapeutic) or poor (subtherapeutic) adherence to c-PAP.
At baseline, anthropometric and metabolic parameters, serum cytokines, and adipose tissue mRNA levels of obesity-associated chemokines and inflammatory markers were not different in OSA and non-OSA subjects. At T1, body weight was significantly reduced in all groups. Serum concentrations of IL-2, IL-4, IL-6, MCP-1, PDGFβ, and VEGFα were reduced by therapeutic c-PAP in OSA subjects and remained unaltered in non-OSA and subtherapeutic c-PAP groups. Similarly, adipose tissue mRNA levels of macrophage-specific (CD68, CD36) and ER stress (ATF4, CHOP, ERO-1) gene markers, as well as of IL-6, PDGFβ, and VEGFα, were decreased only in the therapeutic c-PAP group.
CIH does not represent an additional factor increasing systemic and adipose tissue inflammation in morbid obesity. However, in subjects with OSA, an effective c-PAP therapy improves systemic and obesity-associated inflammatory markers.
Ministero dell'Università e della Ricerca and Progetti di Rilevante Interesse Nazionale.
在患有阻塞性睡眠呼吸暂停(OSA)的肥胖患者中,慢性间歇性低氧(CIH)可能与全身和脂肪组织炎症有关。
我们分别在基线时和减肥干预加持续气道正压通气(c-PAP)或单独减肥干预 24 周后(T1),从 OSA 和非 OSA 肥胖(BMI > 35)受试者中获得腹部皮下脂肪组织活检。OSA 受试者根据 c-PAP 的良好(治疗性)或不良(亚治疗性)依从性进行分组。
在基线时,OSA 和非 OSA 受试者的人体测量和代谢参数、血清细胞因子以及肥胖相关趋化因子和炎症标志物的脂肪组织 mRNA 水平无差异。在 T1,所有组的体重均显著降低。在 OSA 受试者中,治疗性 c-PAP 降低了血清 IL-2、IL-4、IL-6、MCP-1、PDGFβ 和 VEGFα 的浓度,而非 OSA 和亚治疗性 c-PAP 组则保持不变。同样,仅在治疗性 c-PAP 组中,脂肪组织中巨噬细胞特异性(CD68、CD36)和 ER 应激(ATF4、CHOP、ERO-1)基因标志物以及 IL-6、PDGFβ 和 VEGFα 的 mRNA 水平降低。
CIH 并不是病态肥胖患者全身和脂肪组织炎症增加的附加因素。然而,在 OSA 患者中,有效的 c-PAP 治疗可改善全身和肥胖相关的炎症标志物。
意大利大学和研究部以及国家重要利益项目。